Perspectum Lands Top Spot in Alantra Pharma Fast 50 Rankings. Read more
Chief Financial Officer
David Gill has served as our Chief Financial Officer since February 2021. Prior to joining Perspectum, Mr. Gill held several positions at EndoChoice Holdings Inc., a medical technology company, including as Chief Financial Officer from April 2014 until EndoChoice’s acquisition in November 2016, and as President from April 2016 to November 2016. Prior to that and over his career Mr. Gill has served in a variety of senior executive leadership roles for several healthcare companies, including INC Research Holdings, Inc. (now Syneos Health, Inc.), TransEnterix, Inc. (now Asensus Surgical, Inc.), NxStage Medical, Inc., CTI Molecular Imaging, Inc., Novoste Corporation and Dornier Medical Systems, Inc.
Mr. Gill currently serves as a member of the board of directors of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Stonebridge Biopharma plc (NASDAQ: SBBP) and Evolus, Inc (NASDAQ: EOLS), each a public biopharmaceutical company. He started his career as a Certified Public Accountant at Price Waterhouse. Mr. Gill received a B.S. in Accounting from Wake Forest University an M.B.A. from Emory University.